Eliminating a Barrier: Aiming at VISTA, Reversing MDSC-mediated T Cell Suppression in the Tumor Microenvironment

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Sep 17

PMID 39286218

Authors

Yayuan Deng

Mengjia Shi

Lin Yi

Muhammad Naveed Khan

Zhijia Xia

Xiaosong Li

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing remarkable clinical outcomes for patients with various cancer types. However, only a subset of patients benefits from immunotherapeutic interventions due to the primary and acquired resistance to ICIs. Myeloid-derived suppressor cells (MDSCs) play a crucial role in creating an immunosuppressive tumor microenvironment (TME) and contribute to resistance to immunotherapy. V-domain Ig suppressor of T cell activation (VISTA), a negative immune checkpoint protein highly expressed on MDSCs, presents a promising target for overcoming resistance to current ICIs. This article provides an overview of the evidence supporting VISTA's role in regulating MDSCs in shaping the TME, thus offering insights into how to overcome immunotherapy resistance.

Citing Articles

The role of tumor-associated macrophages in lung cancer.

Zhu R, Huang J, Qian F Front Immunol. 2025; 16:1556209.

PMID: 40079009 PMC: 11897577. DOI: 10.3389/fimmu.2025.1556209.

Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide.

Li J, Li X, Liu H Front Pharmacol. 2025; 16:1551115.

PMID: 40051564 PMC: 11882563. DOI: 10.3389/fphar.2025.1551115.

Peng J, Tong L, Liang R, Yan H, Jiang X, Dai Y Int J Genomics. 2025; 2025:5595391.

PMID: 40008397 PMC: 11858721. DOI: 10.1155/ijog/5595391.

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.

Shu Y, Li J Front Immunol. 2025; 16:1526296.

PMID: 39949776 PMC: 11821639. DOI: 10.3389/fimmu.2025.1526296.

Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis.

Wang A, Yan S, Jiang W, Chen X, Huang Y, Zu X BMC Cancer. 2025; 25(1):211.

PMID: 39920578 PMC: 11804071. DOI: 10.1186/s12885-025-13537-x.

References

Peek E, Song W, Zhang H, Huang J, Chin A . Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. Prostate. 2015; 75(5):463-73. DOI: 10.1002/pros.22932. View

Ceeraz S, Eszterhas S, Sergent P, Armstrong D, Ashare A, Broughton T . VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes. Arthritis Res Ther. 2017; 19(1):270. PMC: 5721690. DOI: 10.1186/s13075-017-1474-y. View

Mahoney K, Freeman G . Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2019; 21(1):13-16. DOI: 10.1038/s41590-019-0563-2. View

Tang Y, Zhu J, Huang D, Hu X, Cai Y, Song X . Mandibular osteotomy-induced hypoxia enhances osteoclast activation and acid secretion by increasing glycolysis. J Cell Physiol. 2018; 234(7):11165-11175. DOI: 10.1002/jcp.27765. View

Harvey Z, Chen Y, Jarosz D . Protein-Based Inheritance: Epigenetics beyond the Chromosome. Mol Cell. 2017; 69(2):195-202. PMC: 5775936. DOI: 10.1016/j.molcel.2017.10.030. View

Mehta N, Maddineni S, Kelly R, Lee R, Hunter S, Silberstein J . An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020; 10(1):15171. PMC: 7494997. DOI: 10.1038/s41598-020-71519-4. View

Hosseinkhani N, Derakhshani A, Shadbad M, Argentiero A, Racanelli V, Kazemi T . The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol. 2021; 12:676181. PMC: 8172140. DOI: 10.3389/fimmu.2021.676181. View

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Furumoto H . Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers. Cancer Immunol Immunother. 2022; 71(12):2869-2879. PMC: 10673684. DOI: 10.1007/s00262-022-03205-5. View

10.

Xu J, Luo Y, Yuan C, Han L, Wu Q, Xu L . Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration. Int J Biol Sci. 2020; 16(9):1563-1574. PMC: 7097922. DOI: 10.7150/ijbs.41653. View

11.

Xu W, Hiu T, Malarkannan S, Wang L . The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018; 15(5):438-446. PMC: 6068175. DOI: 10.1038/cmi.2017.148. View

12.

Najjar Y, Finke J . Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3:49. PMC: 3597982. DOI: 10.3389/fonc.2013.00049. View

13.

Zhang K, Zakeri A, Alban T, Dong J, Ta H, Zalavadia A . VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Rep. 2024; 43(1):113661. PMC: 10851928. DOI: 10.1016/j.celrep.2023.113661. View

14.

Yu C, Fitzpatrick A, Cong D, Yao C, Yoo J, Turnbull A . Nitric oxide induces human CLACD25Foxp3 regulatory T cells with skin-homing potential. J Allergy Clin Immunol. 2017; 140(5):1441-1444.e6. DOI: 10.1016/j.jaci.2017.05.023. View

15.

Law A, Valdes-Mora F, Gallego-Ortega D . Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 2020; 9(3). PMC: 7140518. DOI: 10.3390/cells9030561. View

16.

Bao M, Chak-Lui Wong C . Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021; 10(7). PMC: 8304710. DOI: 10.3390/cells10071715. View

17.

Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E . Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021; 218(4). PMC: 7879582. DOI: 10.1084/jem.20201803. View

18.

Reis E, Mastellos D, Ricklin D, Mantovani A, Lambris J . Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2017; 18(1):5-18. PMC: 5816344. DOI: 10.1038/nri.2017.97. View

19.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

20.

Liu J, Lin W, Xiao Y, Yang Q, Bushabu Fidele N, Yu H . VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma. Int Immunopharmacol. 2023; 125(Pt A):111128. DOI: 10.1016/j.intimp.2023.111128. View